Latest in Wegovy's
Sort by
9 items
-
The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide — while adding great heft to the economy of Novo Nordisk’s home country, Denmark.Top stories - CBS News - Yesterday -
How a love story launched the company behind Ozempic, Wegovy
Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, were looking for a way to tackle diabetes, which the wife suffered from.Top stories - CBS News - Yesterday -
Wegovy's creator invested £6bn in this town. So why is it not booming?
Europe's most valuable company has invested billions in Kalundborg on Denmark's coast - but it has many problems.Top stories - BBC News - 2 days ago -
Ozempic and Wegovy Ease Knee Osteoarthritis Pain in Large Study
A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current medications in alleviating symptoms.Health - The New York Times - 4 days ago -
Ozempic and Wegovy considered 'available' after more than 2 years in shortage
The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of being considered in shortage by the Food and Drug Administration (FDA). ...Politics - The Hill - 5 days ago -
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.Business - CNBC - 5 days ago -
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make safely.Business - CNBC - October 23 -
Weight loss injections: How do drugs like Wegovy and Mounjaro work?
NHS experts report unprecedented demand for the new generation of obesity treatments.Top stories - BBC News - October 18